Improvements demonstrated in all key exploratory efficacy endpoints - percent change in EASI, EASI-50, vIGA and pruritis NRS - at four weeks following once-daily oral treatment with RPT193
• Further improvement in percent change in EASI, EASI-50 and vIGA observed with RPT193 two weeks after end of treatment• RPT193 was well tolerated with no serious adverse events
• RAPT plans to advance RPT193 to Phase 2b clinical trial in atopic dermatitis
• Management to host webcast conference call today at 8:30 a.m. ET
Conference call and webcast details
RAPT hosedt a conference call accompanied by a slide presentation today, Monday, June 14, 2021, at 8:30 a.m. ET. The live webcast and audio archive of the presentation is available on the RAPT Therapeutics website at https://investors.rapt.com/events-and-presentations. The call can be accessed by dialing (833) 672-0665 (domestic) or (929) 517-0344 (international) and referring to conference ID 4696044. The webcast replay will be available for 30 days.
RAPT hosedt a conference call accompanied by a slide presentation today, Monday, June 14, 2021, at 8:30 a.m. ET. The live webcast and audio archive of the presentation is available on the RAPT Therapeutics website at https://investors.rapt.com/events-and-presentations. The call can be accessed by dialing (833) 672-0665 (domestic) or (929) 517-0344 (international) and referring to conference ID 4696044. The webcast replay will be available for 30 days.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.